PDCD1 and lung carcinoma: The targeting of TGF-β1, which is abundant in platelet α-granules, represents another strategy that not only regulates the pro-tumorigenic activity of these cells but also attenuates the resistance of lung cancer to PD-1/PD-L1-directed immunotherapy [150,151,152].